• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Kappos fingolimod moa-clin_results_vfinal_buenosaires1a
 

Kappos fingolimod moa-clin_results_vfinal_buenosaires1a

on

  • 2,221 views

 

Statistics

Views

Total Views
2,221
Views on SlideShare
2,221
Embed Views
0

Actions

Likes
0
Downloads
61
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • THIS IS AN ANIMATED SLIDE WITH 1 CLICK:fades in the orange text box on the right
  • THIS SLIDE CONTAINS A BUILD: The four trials feeding into the orange box appear first with the remainder appearing on click.At filing, fingolimod has the largest clinical trial programme.
  • Absolute lymphocyte count decreases within days of fingolimod administrationLymphocyte count returns to normal levels within weeks of treatment cessationLymphocytes are not destroyed and remain functional within the lymph nodes during fingolimod treatmentNo rebound effect; absolute lymphocyte count remains within normal range (approximately 1 to 4 x 109/L)Circulating lymphocytes in blood represent <2% of total number of lymphocytes Reported fingolimod-induced apoptosis of human lymphocytes in vitro (Suzuki S. et al. Immunology 1996) was at concentrations of 2 to 10 µM, significantly higher than the low nM concentrations at which in vivo activity has been observed.Source: ISS PTT 11.1-1Mean lymphocyte counts were returning to within the normal range in the first 45 days afterdiscontinuation. At the 3-month time point, the increase from study drug discontinuation wasmarked in FTY720 treatment groups. Only a minority of patients were followed for longer periods so thatthe information on the recovery beyond 3 months is limited.

Kappos fingolimod moa-clin_results_vfinal_buenosaires1a Kappos fingolimod moa-clin_results_vfinal_buenosaires1a Presentation Transcript

  • Fingolimod (Gilenya):Mode of ActionandClinical Trial Results
    Prof. Ludwig Kappos
    Chair Neurology and Department of Biomedicine
    University Hospital
    CH-4031 Basel
  • Disclosure
    L.K. is the Principal Investigator for the FTY 720 Phase II and FREEDOMS studies and has received research support from Actelion, Advancell, Allozyne, BaroFold, Bayer Health Care Pharmaceuticals, Bayer Schering Pharma, Bayhill, Biogen Idec, BioMarin, CLC Behring, Elan, Genmab, Genmark, GeNeuro SA, GlaxoSmithKline, Lilly, Merck Sereno, Medicinova, Novartis, Novo Nordisk, Peptimmune, Sanofi-Aventis, Santhera, Roche, Teva, UCB and Wyeth
  • Disease Modifying Treatments (DMT) in MS(Immunomodulation/-suppression)
    GA
    Patients
    with RR MS
    Available therapies
    IFNB
    ?
    ?
    FTY 720
    Emerging Therapies and strategies
    Natalizumab
    Oral Immuno-modulators
    • Fumaric acid*
    • Laquinimod*
    • Teriflunomide*
    • oral VLA4-antagonists
    • Temsirolimus
    • Mycophenolic acid
    • Statins
    • Others…
    Mitoxantrone
    Cytotoxic agents
    • Cladribine*
    • Pixantrone
    • Treosulfane
    Ag-specific
    Therapies
    • Altered peptide- Ligands
    • MBP-, DNA- vaccination
    • T-cell-, TCR-
    vaccination
    Combination Therapy
    • IFNB-based
    • GA-based
    • Novel agents
    Monoclonal Antibodies
    • Alemtuzumab*
    • Rituximab
    • Ocrelizumab
    • Ofetimumab
    • (Atacicept)
    • Daclizumab
    In yellow: agents in Phase III; *recently completed Phase III
  • O
    H
    O
    H
    N
    H
    2
    Fingolimod - a structural analogue of natural sphingosine1
    • Sphingosine 1-phosphate (S1P) is a naturally occurring bioactive sphingolipid that plays a key role in inflammation and repair
    • Both sphingosine and fingolimod are phosphorylated by ubiquitous intracellular sphingosine kinases to their active forms and act via S1P receptors2 (G protein-coupled receptors, discovered in 19983)
    Sphingosine
    O
    H
    H
    O
    Fingolimod
    N
    H
    2
    1. Brinkmann V and Lynch KR. Curr Opin Immunol 2002; 2. Anliker B and Chun J. J Biol Chem 2004; 3. Lee MJ et al. Science 1998
  • S1P1
    S1P3
    S1P4
    S1P5
    Effects
    Fingolimod-phosphate acts on four of five sphingosine 1-phosphate receptors1
    Neural cells, EC,
    atrial myocytes, SMC
    Lymphocytes, neural cells, EC, atrial myocytes, SMC
    CNS,oligodendrocytes,natural killer cells
    Lymphocytes (low expression)
    Endothelial cell function, vasomotor tone and heart rate5–7
    Lymphocyte egress fromlymph nodes2–4
    CNS cell function and migration6,8,9
    EC, endothelial cells; SMC, smooth muscle cells; S1P, sphingosine 1-phosphate 1. Chun J and Hartung HP. Clin Neuropharmacol 2010; 2. Mandala S et al. Science 2002; 3. Baumruker T et al. Expert Opin Investig Drugs 2007; 4. Matloubian M et al. Nature 2004; 5. Brinkmann V. Pharmacol Ther 2007; 6. Mizugishi K et al. Mol Cell Biol 2005; 7. Massberg S andvon Andrian UH. N Engl J Med 2006; 8. Kimura A et al. Stem Cells 2007; 9. Jaillard C et al. J Neurosci 2005
  • (Mehling M et al, Neurology 2011)
  • Fingolimod selectively modulates T cell recirculation through lymphoid organs
    Blood (10x109)
    <2% of total lymphocytes
    S1P1
    favors egress and overrides CCR7
    CCR7
    Mediates retention in the lymph node
    Tissue
    (290 x 109)
    X
    TEM
    TCM
    Loss of
    CCR7
    Lymph node
    (190 x 109 )
    T naive
    T activated
    CCR7-
    CCR7+
    Fingolimod
    • Fingolimod induces internalization of S1P1 thereby favoring selective retention of CCR7+ Tnaive and TCM (incl. Th17) cells involved in MS pathology.
    • TEM, which are important for immune surveillance and maintenance of protective immunity, lack the homing and retention-promoting receptor CCR7, and are therefore largely spared by fingolimod.
    Tn, naive T cells; TCM, central memory T cell; TEM, effector memory T cell
    Sallusto et al, Nature 1999; Mackay Nature 1999; Sallusto et al., Annu Rev Immunol 2004; Lanzavecchia et al Science 2000; Appay et al, Cytometry 2008; Westermann J and Pabst R. Clin Investig 1992; Pham et al, Immunity 2008
  • Fingolimod has prophylactic and therapeutic effects in EAE rat model of MS1
    Vehicle-treated
    3.5
    3.0
    2.5
    2.0
    Clinical score ± SEM
    1.5
    1.0
    0.5
    0.0
    0
    5
    10
    15
    20
    25
    30
    35
    40
    45
    50
    55
    Days post-immunisation
    EAE, experimental autoimmune encephalomyelitis
    1. Foster CA et al. Brain Pathol 2009
  • Fingolimod has prophylactic and therapeutic effects in EAE rat model of MS1
    Prophylactic Day 0-11
    Vehicle-treated
    Fingolimod† prophylactic
    3.5
    3.0
    2.5
    2.0
    Clinical score ± SEM
    1.5
    1.0
    0.5
    ***
    0.0
    0
    5
    10
    15
    20
    25
    30
    35
    40
    45
    50
    55
    Days post-immunisation
    †Fingolimod dose 0.3 mg/kg; ***p≤0.001; EAE, experimental autoimmune encephalomyelitis
    1. Foster CA et al. Brain Pathol 2009
  • Fingolimod has prophylactic and therapeutic effects in EAE rat model of MS1
    Prophylactic Day 0-11
    Therapeutic Day 12-28
    Vehicle-treated
    Fingolimod† prophylactic
    Fingolimod† therapeutic
    3.5
    3.0
    2.5
    2.0
    Clinical score ± SEM
    1.5
    1.0
    0.5
    ***
    ***
    0.0
    0
    5
    10
    15
    20
    25
    30
    35
    40
    45
    50
    55
    Days post-immunisation
    †Fingolimod dose 0.3 mg/kg; ***p≤0.001; EAE, experimental autoimmune encephalomyelitis
    1. Foster CA et al. Brain Pathol 2009
  • Fingolimod has prophylactic and therapeutic effects in EAE rat model of MS1
    Prophylactic Day 0-11
    Therapeutic Day 12-28
    Rescue
    Day 40-53
    Vehicle-treated
    Fingolimod† prophylactic
    Fingolimod† therapeutic
    Fingolimod† rescue
    3.5
    3.0
    2.5
    2.0
    Clinical score ± SEM
    ***
    1.5
    1.0
    0.5
    ***
    ***
    0.0
    0
    5
    10
    15
    20
    25
    30
    35
    40
    45
    50
    55
    Days post-immunisation
    †Fingolimod dose 0.3 mg/kg; ***p≤0.001; EAE, experimental autoimmune encephalomyelitis
    1. Foster CA et al. Brain Pathol 2009
  • Fingolimod treatment restores nerve conduction in EAE
    MOG-induced relapsing-remitting EAE in DA rats
    Neuronal function determined by recording SEP
    Treatment
    SEP (electrical stimulation)
    4.0
    Fingolimod
    Control
    3.0
    N2
    EPrecording
    2.0
    Clinical score
    SEP recordings Day 53
    1.0
    Naïve
    Positive control
    P1
    0.0
    Fingolimod
    0
    55
    5
    10
    15
    20
    25
    30
    35
    40
    45
    50
    Days post-immunisation
    Clinical score: 1, flaccid tail; 2, hind limb weakness or ataxia; 3, full paralysis of hind limbs
    Fingolimod preserved and maintained electrophysiological nerve conduction in EAE
    DA, dark agouti; EAE, experimental autoimmune encephalomyelitis; MOG, myelin-oligodendrocyte glycoprotein; SEP, somatosensory-evoked action potentials Balatoni B et al. Brain Res Bulletin 2007
  • Proof of Concept in MS
  • 2006;355:1124-40
    FTY- Phase II, POC study
    (NEJM 2006;355:1124-40)
  • Fingolimod Phase II study: patients free from Gd+ lesions after 5 years
    Placebo re-randomised
    to fingolimod
    100
    95.6%
    98.1%
    93.0%
    89.3%
    80
    96.1%
    91.7%
    87.5%
    86.9%
    91.1%
    89.7%
    88.7%
    81.0%
    83.1%
    85.9%
    Patients free from Gd+ lesions (%)*
    79.2%
    60
    PlaceboPlacebo / fingolimodFingolimod 1.25 mgFingolimod 5.0 mg / 1.25 mg
    78.2%
    76.7%
    40
    47.0%
    0
    0
    1
    2
    3
    4
    5
    6
    12
    24
    36
    48
    60
    (n = 220)
    (n = 188)
    (n = 170)
    (n = 149)
    (n = 140)
    (n = 266)
    (n = 278)
    (n = 261)
    (n = 260)
    (n = 266)
    (n = 254)
    (n = 260)
    Time (months)
    *Calculated at each time point using the number of patients with an available MRI scan as the denominator
    Extension phase ITT population
    Kappos L et al. ECTRIMS 2009, Montalban et al. MSJ 2011
  • Annualize Relapse Rates in Different Epochs of the POC Study by Completion Status and Randomization
  • Phase II Study – Key findings:
    Pronounced antiinflammatory effect on MRI outcomes
    Already after 6 mths significant ARR reduction by 50%
    Identical effect with lower dose (1.25mg) that was thought not to be effective in preventing transplant rejection
    No indication of decreasing efficacy over > 6 years, good tolerability
    Valuable data about selective effects on immune cells
  • Fingolimod selectively inhibits naïve and central memory T cell egress but spares effector memory T cells
    p<0.001
    p<0.001
    80
    Selective retention: immunological effector functions are preserved
    70
    60
    p<0.001
    50
    Percentage of CD4+ cells
    40
    30
    Untreated MS
    Fingolimod-treated MS
    20
    10
    0
    Effector memory T cells(CCR7-CD45RA- [TEM] and CCR7-CD45RA+ [TEMRA])
    Naïve
    (CCR7+CD45RA+)
    Central memory T cells(CCR7+CD45RA-)
    Adapted from Mehling M et al. Neurology 2008
  • Fingolimod reduces the proportion of Th17 cells in the circulation of people with MS*
    1.5
    Pro-inflammatory Th17 cells reside mainly in the TCM pool and are enriched in the CSF and lesions of MS patients1–3
    p<0.01
    p<0.01
    p<0.01
    Fingolimodtreatment
    1.0
    IL17+ T cells (%) in CD4+ T cells*
    0.5
    Fingolimod reduces the proportion of circulating Th17 cells in people with MS
    0.0
    Fingolimod-treated MS
    Healthy donors
    Untreated MS
    IFNβ-treated MS
    * Mehling M et al. Neurology 2010; Purified blood T cells from patients with MS treated with fingolimod during the Phase II study and controls. Flow cytometry analysis of IL-17 producing CD4+ T cells.
    1. Tzartos JS et al. Am J Pathol 2008; 2. Kébir et al. Ann Neurol 2009; 3.Brucklacher-Waldert et al. Brain 2009. TCM, central memory T cell
  • from POC to Clinical Practice
  • INFORMS
    PPMS
    n ~ 900
    Japan
    RRMS
    n = 168
    FREEDOMS II
    (vs placebo)
    in RRMS
    n = 1083
    > 5000 people with MS treated with fingolimod + 1079 (pharmacology)
    Fingolimod Clinical Development
    FREEDOMS (vs placebo)
    in RRMS
    n = 1272
    TRANSFORMS (vs IFNB1a qw)
    in RRMS
    n = 1292
    Phase II
    POC Study (2201) in
    RRMS(+SPMS)
    n = 281
    Pharmacology trials
    n = 1079
    Phase III
    2845 patients with relapsing MS in completed clinical studies + 1079 in short term pharmacology trials
    Ongoing
    Ongoing
    POC: proof of concept
  • FREEDOMS: Phase III study of fingolimod vs placebo in RRMS (N = 1272)
    24-month, randomised, double-blind, placebo-controlled, parallel-group, multicentre study
    Extension study
    (fingolimod 0.5 mg)
    MRI
    Once-daily fingolimod 0.5 mg capsule
    Visit
    Once-daily fingolimod 1.25 mg capsule
    Once-daily placebo capsule
    Month 6
    Month 12
    Month 24
    Randomisation
    Kappos L et al. N Engl J Med 2010
  • FREEDOMS: baseline characteristics
    1272 patients in 22 countries across Europe, Canada, Australia, Israel, Russia and South Africa
    ITT population
    Kappos L et al. N Engl J Med 2010
  • FREEDOMS: Effect on annualised relapse rate vs placebo
    −54% vs placebo
    p<0.001
    −60% vs placebo
    p<0.001
    0.4
    0.40
    (0.34–0.47)
    0.3
    Annualised relapse rate (95% CI)
    0.2
    0.18
    (0.15–0.22)
    0.16
    (0.13–0.19)
    0.1
    0.0
    Placebo
    (n = 418)
    Fingolimod 0.5 mg
    (n = 425)
    Fingolimod 1.25 mg
    (n = 429)
    ITT population
    Kappos L et al. N Engl J Med 2010
  • FREEDOMS:Effect on risk of disability progression confirmed after 3 or 6 months, at 2 years
    30% reductionin risk of progression
    (HR: 0.70 vs placebo)†
    37% reductionin risk of progression
    (HR: 0.63 vs placebo)†
    PlaceboFingolimod 0.5 mg
    FREEDOMS 2-year results1
    30
    24.1%
    p=0.02 for fingolimod vs placebo*
    Patients with EDSS progression confirmed after 3 months (%)
    20
    17.7%
    10
    0
    0
    90
    180
    270
    360
    450
    540
    630
    720
    30
    Patients with EDSS progression confirmed after 6 months (%)
    19.0%
    20
    p=0.01 for fingolimod vs placebo*
    10
    12.5%
    0
    0
    90
    180
    270
    360
    450
    540
    630
    720
    Time (days)
    *Log-rank test comparing the survival distributions between treatment groups; †Cox’s proportional hazard model adjusted for treatment, country, baseline EDSS and age
    1. Kappos L et al. N Engl J Med 2010; 362: 387-401.
  • MRI
    EDSS
    Clinical visit
    TRANSFORMS: Phase III study of fingolimod vs IFNβ-1a IM qw in RRMS (N = 1292)
    12-month, randomised, double-blind, double-dummy, active-control, multicentre study
    Extension study
    (fingolimod 0.5 mg)
    Once-daily fingolimod 0.5 mg capsule
    and matching weekly placebo IM
    Once-daily fingolimod 1.25 mg capsule
    and matching weekly placebo IM
    Once-weekly IFNβ-1a 30 µg IM
    and matching daily placebo capsule
    Ongoing
    Randomisation
    Month 12
    Month 6
    Cohen JA et al. N Engl J Med 2010
  • TRANSFORMS: baseline characteristics
    1292 patients in 18 countries across Europe, Canada, Australia, Israel, Russia and South Africa
    Randomised population
    Cohen JA et al. N Engl J Med 2010
  • TRANSFORMS: Annualised relapse rate vs IFNβ-1a IM
    −52% vs IFNβ-1a
    p<0.001
    −38% vs IFNβ-1a
    p<0.001
    (0.26–0.42)
    Annualised relapse rate (95% CI)
    (0.16–0.26)
    (0.12–0.21)
    IFNβ-1a IM(n = 431)
    Fingolimod 0.5 mg(n = 429)
    Fingolimod 1.25 mg(n = 420)
    ITT population
    Cohen JA et al. N Engl J Med 2010
  • Phase III clinical outcome measures: Efficacy summary
    *p≤0.05; **p≤0.01; ***p≤0.001MSFC, MS functional composite
  • Subgroup Analysis I: ARR Ratios for Fingolimod versus Comparator (95% Confidence Intervals) by Baseline Demographics
    FREEDOMS 2-year results2
    TRANSFORMS 1-year results1
    Favors fingolimod
    Favors fingolimod
    Favors IFNb-1a IM
    Favors placebo
    Sex
    Sex
    0.50 (0.39–0.64)
    0.44 (0.32–0.62)
    Female (n = 594)
    Female (n = 573)
    0.61 (0.37–1.01)
    0.33 (0.22–0.50)
    Male (n = 249)
    Male (n = 287)
    Age (years)
    Age (years)
    0.41 (0.28–0.58)
    0.33 (0.25–0.43)
    ≤ 40 (n = 544)
    ≤ 40 (n = 562)
    0.76 (0.54–1.09)
    0.68 (0.42–1.10)
    > 40 (n = 299)
    > 40 (n = 298)
    Previous treatment
    Previous treatment
    0.45 (0.27–0.75)
    0.36 (0.27–0.49)
    Untreated (n = 493)
    Untreated (n = 366)
    0.50 (0.36–0.70)
    0.54 (0.39–0.73)
    Treated (n = 350)
    Treated (n = 494)
    0.2
    0.4
    0.6
    0.8
    1.0
    1.2
    1.4
    0.2
    0.4
    0.6
    0.8
    1.0
    1.2
    1.4
    1., 2. :Cohen J et al NEJM 2010; Kappos L et al NEJM 2010; von Rosenstiel P et al. ECTRIMS 2010 (poster)
  • Subgroup Analysis II: ARR Ratios for Fingolimod versus Comparator (95% Confidence Intervals) by Baseline Disease Activity
    FREEDOMS 2-year results2
    TRANSFORMS 1-year results1
    Favors fingolimod
    Favors placebo
    Favors fingolimod
    Favors IFNb-1a IM
    High disease activity at baseline*
    High disease activity at baseline*
    0.48 (0.24–0.94)
    0.37 (0.24–0.57)
    Yes (n = 140)
    Yes (n = 121)
    0.51 (0.37–0.70)
    0.46 (0.36–0.59)
    No (n = 701)
    No (n = 734)
    Number of Gd-enhancing T1 lesions at baseline
    Number of Gd-enhancing T1 lesions at baseline
    0.56 (0.39–0.81)
    0.48 (0.36–0.65)
    0 (n = 525)
    0 (n = 556)
    0.44 (0.28–0.69)
    0.40 (0.29–0.55)
    ≥ 1 (n = 315)
    ≥ 1 (n = 296)
    Number of relapses in year before study
    Number of relapses in year before study
    0.53 (0.36–0.78)
    0.52 (0.39–0.69)
    0 or 1 (n = 528)
    0 or 1 (n = 535)
    0.43 (0.29–0.65)
    0.37 (0.27–0.51)
    > 1 (n = 315)
    > 1 (n = 325)
    Number of relapses in 2 years before study
    Number of relapses in 2 years before study
    0.50 (0.27–0.91)
    0.37 (0.24–0.58)
    1 (n = 256)
    1 (n = 239)
    0.49 (0.31–0.76)
    0.45 (0.32–0.63)
    2 (n = 360)
    2 (n = 362)
    0.50 (0.32–0.78)
    0.50 (0.34–0.72)
    > 2 (n = 226)
    > 2 (n = 258)
    0.2
    0.4
    0.6
    0.8
    1.0
    1.2
    1.4
    0.2
    0.4
    0.6
    0.8
    1.0
    1.2
    1.4
    *High disease activity was defined as ≥1 Gd-enhancing lesion at baseline and ≥2 relapses in the year prior to the study
    1., 2. :Cohen J et al NEJM 2010; Kappos L et al NEJM 2010; von Rosenstiel P et al. ECTRIMS 2010 (poster)
  • Subgroup Analysis III: ARR Ratios for Fingolimod versus Comparator (95% Confidence Intervals) by Baseline Disease Severity
    FREEDOMS 2-year results2
    TRANSFORMS 1-year results1
    Favors fingolimod
    Favors fingolimod
    Favors IFNb-1a IM
    Favors placebo
    Baseline EDSS score
    Baseline EDSS score
    0.46 (0.33–0.63)
    0.48 (0.38–0.60)
    0.0–3.5 (n = 709)
    0.0–3.5 (n = 733)
    0.57 (0.31–1.08)
    0.34 (0.20–0.58)
    ≥ 4.0 (n = 134)
    ≥ 4.0(n = 127)
    Baseline T2 lesion volume (mm3)
    Baseline T2 lesion volume (mm3)
    0.50 (0.33–0.74)
    0.40 (0.29–0.57)
    ≤ 3300 (n = 418)
    ≤ 3300 (n = 477)
    0.47 (0.36–0.63)
    0.50 (0.34–0.75)
    > 3300 (n = 422)
    > 3300 (n = 376)
    0.2
    0.4
    0.6
    0.8
    1.0
    1.2
    1.4
    0.2
    0.4
    0.6
    0.8
    1.0
    1.2
    1.4
    1., 2. :Cohen J et al NEJM 2010; Kappos L et al NEJM 2010; von Rosenstiel P et al. ECTRIMS 2010 (poster)
  • FREEDOMS: 3-Month Confirmed Disability ProgressionKM (SE) estimates by sub-group
    KM, Kaplan Meier; SE, Standard Error
  • FREEDOMS: 3-Month Confirmed Disability ProgressionKM (SE) estimates by sub-group
    Havrdova E et al ENS 2011
  • FREEDOMS: 3-Month Confirmed Disability ProgressionKM (SE) estimates by sub-group
    Havrdova E et al ENS 2011
  • Effects on MRI Outcomes
  • Phase 3 MRI Outcome Measures – Mean Reductions Relative to Control
    *p<0.05; **p<0.01; ***p<0.001
    38
  • Phase III MRI Outcome Measures –Mean Reductions Relative to Control
    *p<0.05; **p<0.01; ***p<0.001
    39
  • 12
    6
    24
    0
    0
    **
    -0.2
    **
    ***
    -0.4
    *
    -0.6
    ***
    ***
    -0.8
    ***
    ***
    -1.0
    -1.2
    -1.4
    Fingolimod Phase III Studies:Brain volume changes compared to Placebo, IFNB1a and healthy individuals
    Time (months)
    TRANSFORMSOverall rate of brain atrophy reduced by 31-33% with fingolimod over 1 year vs IFNb-1a
    FREEDOMSOverall rate of brain atrophy reduced by 32-36% with fingolimod over 2 years vs placebo
    Mean change from baseline (%)
    FREEDOMS1
    TRANSFORMS2
    Fingolimod 1.25 mg
    Fingolimod 1.25 mg
    Fingolimod 0.5 mg
    Fingolimod 0.5 mg
    Placebo
    IFNβ-1a
    Evaluable ITT population. *p<0.05 for fingolimod vs placebo; **p<0.01 for fingolimod vs placebo; ***p≤0.001 for fingolimod vs placebo / IFNβ-1a 1. Kappos L et al. N Engl J Med 2010; 2. Cohen JA et al. N Engl J Med 2010
  • 12
    6
    24
    0
    0
    **
    -0.2
    **
    ***
    -0.4
    *
    -0.6
    ***
    ***
    -0.8
    ***
    ***
    -1.0
    -1.2
    -1.4
    Fingolimod Phase III Studies:Brain volume changes compared to Placebo, IFNB1a and healthy individuals
    Time (months)
    Mean change from baseline (%)
    FREEDOMS1
    TRANSFORMS2
    Fingolimod 1.25 mg
    Fingolimod 1.25 mg
    Fingolimod 0.5 mg
    Fingolimod 0.5 mg
    Placebo
    IFNβ-1a
    Green shaded area represents the estimated rate of brain volume loss in healthy individuals (0.2–0.4% per year)3,4
    Evaluable ITT population. *p<0.05 for fingolimod vs placebo; **p<0.01 for fingolimod vs placebo; ***p≤0.001 for fingolimod vs placebo / IFNβ-1a 1. Kappos L et al. N Engl J Med 2010; 2. Cohen JA et al. N Engl J Med 2010; 3. Fotenos AF et al. Arch Neurol 2008; 4. Simon JH. Mult Scler 2006
  • #O280, Kappos et al
    Change in brain volume in FREEDOMS
    FREEDOMS 12- and 24-month data
    Fingolimod 0.5 mg
    (n = 357)†
    Fingolimod 1.25 mg
    (n = 334)†
    Placebo
    (n = 331)†
    0.0
    -0.2
    -0.44**
    -0.50*
    -0.4
    -0.65
    -0.6
    Mean brain volume change (%)
    -0.34
    -0.45
    -0.8
    P <0.001
    P <0.001
    -1.0
    -1.2
    -0.66
    -1.4
    Month 0-12
    Month 12-24
    *p=0.03 vs placebo at Month 12; **p=0.001 vs placebo at Month 12; †evaluable patients at Month 24.
    Kappos L et al, ENS 2011
  • Effects of Fingolimod on Brain Volumein FREEDOMS / TRANSFORMS
    FREEDOMS1 – 24 M data
    TRANSFORMS2 – 12 M data
    Fingolimod 0.5 mg
    (n = 357)†
    Fingolimod 1.25 mg
    (n = 334)†
    Fingolimod 0.5 mg
    (n = 368)
    Fingolimod 1.25 mg
    (n = 345)
    Placebo
    (n = 331)†
    IFNβ-1a IM
    (n = 359)
    0.0
    0.0
    -0.30
    -0.2
    -0.31
    -0.2
    -0.45
    -0.44**
    -0.50*
    -0.4
    -0.4
    -0.65
    -0.6
    -0.6
    Mean Change in Brain Volume at 12 M
    as compared to Baseline (%)
    Mean Change in Brain Volume at 12 and 24 M
    as compared to Baseline (%)
    -0.34
    -0.45
    -0.8
    -0.8
    -1.0
    -1.0
    p<0.001
    vs Placebo at M 24
    p<0.001
    vs Placebo at M 24
    p<0.001
    vs IFNβ-1a
    at M 12
    p<0.001
    vs IFNβ-1a
    At M 12
    -1.2
    -1.2
    -0.66
    -1.4
    -1.4
    Months 0-12
    Months 12-24
    Evaluable ITT population. FREEDOMS: *p=0.03 vs Placebo at M 12; **p=0.001 vs Placebo at M 12; †Evaluable patients at M 24
    1. Kappos L et al. N Engl J Med 2010; 2. Cohen JA et al. N Engl J Med 2010
  • FREEDOMS: Effect on PBVC by baseline Gd-lesion status
    #O280, Kappos et al
    A
    Time (months)
    B
    Time (months)
    Mean change from baseline(%)
    Mean change from baseline(%)
    • Brain volume decreased more rapidly in patients with Gd-enhancing lesions at baseline (A) than in patients without these lesions (B) , irrespective of treatment group
    • Both fingolimod doses significantly reduced the rate of brain volume loss versus placebo, irrespective of baseline inflammatory lesion status
    Kappos L et al, ENS 2011
  • Effects of Fingolimod on Brain Volumein FREEDOMS / TRANSFORMS
    FREEDOMS1 – 24 M data
    TRANSFORMS2 – 12 M data
    Fingolimod 0.5 mg
    (n = 357)†
    Fingolimod 1.25 mg
    (n = 334)†
    Fingolimod 0.5 mg
    (n = 368)
    Fingolimod 1.25 mg
    (n = 345)
    Placebo
    (n = 331)†
    IFNβ-1a IM
    (n = 359)
    0.0
    0.0
    -0.30
    -0.2
    -0.31
    -0.2
    -0.45
    -0.44**
    -0.50*
    -0.4
    -0.4
    -0.65
    -0.6
    -0.6
    Mean Change in Brain Volume at 12 M
    as compared to Baseline (%)
    Mean Change in Brain Volume at 12 and 24 M
    as compared to Baseline (%)
    -0.34
    -0.45
    -0.8
    -0.8
    -1.0
    -1.0
    p<0.001
    vs Placebo at M 24
    p<0.001
    vs Placebo at M 24
    p<0.001
    vs IFNβ-1a
    at M 12
    p<0.001
    vs IFNβ-1a
    At M 12
    -1.2
    -1.2
    -0.66
    -1.4
    -1.4
    Months 0-12
    Months 12-24
    Evaluable ITT population. FREEDOMS: *p=0.03 vs Placebo at M 12; **p=0.001 vs Placebo at M 12; †Evaluable patients at M 24
    1. Kappos L et al. N Engl J Med 2010; 2. Cohen JA et al. N Engl J Med 2010
  • 0.6
    0.5
    (1.86)
    0.5
    0.4
    Number of Gd-enhancing T1 lesions,
    mean (SD)
    0.3
    0.2
    (0.87)
    0.2
    (0.97)
    0.2
    (0.94)
    0.2
    0.1
    (0.43)
    0.1
    (0.58)
    0.1
    0
    12
    (n=354)
    12
    (n=374)
    12
    (n=352)
    24
    (n=273)
    24
    (n=308)
    24
    (n=280)
    month
    Continuous fingolimod
    0.5 mg
    Continuous fingolimod
    1.25 mg
    IFNβ-1a to fingolimod
    TRANSFORMS-24 Mth follow-up: Sustained fingolimod 0.5 mg or 1.25 mg treatment compared with switching to fingolimod after 12 months treatment with IFNβ-1a:
    Number of Gd-enhancing lesions at months 12 and 24
  • TRANSFORMS-24 Mth follow-up: Sustained fingolimod 0.5 mg or 1.25 mg treatment compared with switching to fingolimod after 12 months treatment with IFNβ-1a: % change of normalized brain volume
    Khatri B et al, Lancet Neurology 2011
  • #O280, Kappos et al
    Conclusions from brain volume measurements
    • Over 2 years, fingolimod therapy significantly reduced the overall rate of brain volume loss, irrespective of inflammatory Gd-enhancing lesions at baseline.
    • Brain volume loss occurred more quickly in patients with, than in those without, Gd-enhancing lesions at baseline, irrespective of treatment group.
    • In patients withoutGd-lesions at baseline the reduction in brain volume loss was apparent within the first 6 months and was sustained over the 2-year study
    • In patients withGd-lesions at baseline the reduction in brain volume loss was more apparent in the 2nd year than the 1st year
    • Despite the anti-inflammatory effect of fingolimod on MRI lesions, which could result in initial pseudoatrophy in Gd+ patients, fingolimod did not lead to a greater rate of brain volume loss compared to placebo (suggestive of a superimposed neuroprotective effect?)
  • Adverse Event Profile and overall Safety
  • Fingolimod adverse event experience
    +Includes all available data from Phase II and Phase III core and extension studies with treatment durations varying between 1 to 6 years – data cut-off from 120 day safety update; *Includes events occurring in patients whose primary or secondary reason for discontinuing the study drug was an AE (including abnormal laboratory findings) **Includes 1 fatal disseminated varicella infection and 1 fatal Herpes simplex Encephalitis (TRANSFORMS)
  • Adverse events of special interest
    +Includes all available data from Phase II and Phase III core and extension studies with treatment durations varying between 1 to 6 years – data cut-off from 120 day safety update
    AV, atrioventricular
  • Effects of Fingolimod on Lymphocytes
  • Lymphocyte count during treatment with fingolimod: FREEDOMS
    Lymphocyte counts dropped rapidly, approaching steady state levels in 2- 4 weeks and remained stable on continued therapy.
    Values represent the mean; error bars are the standard deviation.
    Francis G et al.AAN April 2011; Lymphocytes and Fingolimod Temporal pattern and relationship with Infections (S30.001)
  • Fingolimod leads to Selective and Reversible redistribution of lymphocytes, with no lymphocytotoxicity
    Absolute lymphocyte count (109/L)
    • Rapid redistribution
    • fingolimod reduces blood lymphocyte count within 4-6 hours (max after 1-2 weeks)
    • lymphocytes are retained in the lymph nodes and are not destroyed
    • Reversible effect
    • lymphocyte function is maintained
    Recovery to normal levels within 1-2 months
    LLN
    LLN, lower limit of normal range; Population: all fingolimod-treated patients in MS trials who discontinued treatment. Francis et al ECTRIMS 2010
  • Infections
    *LTRI = Lower respiratory tract infections. Only type of infection with higher incidence (>1% difference vs placebo) in the 1.25 mg group in Phase III. Bronchitis was the most frequently reported LRTI.
    Francis G et al. AAN April 2011; Lymphocytes and Fingolimod Temporal pattern and relationship with Infections (S30.001)
  • InfectionsSimilar incidence in all treatment groupsIncreased incidence in lower respiratory tract infections
    *LTRI = Lower respiratory tract infections. Only type of infection with higher incidence (>1% difference vs. placebo) in the 1.25 mg group in Phase III. Bronchitis was the most frequently reported LRTI.
  • Incidence of overall infections/per year categorized by mean lymphocyte counts: FREEDOMS core study group
    Infections by Lymphocyte Count
    Infections Overall
    2
    1.8
    1.6
    1.4
    1.2
    Incidence rate per patient-year
    of any infections
    1
    0.8
    0.6
    0.4
    0.2
    0
    <0.2
    (n=23)
    0.2-0.3
    0.3-0.4
    0.4-0.5
    0.5-0.7
    >0.7
    Placebo
    Fingolimod
    Fingolimod
    (n=169)
    (n=194)
    (n=169)
    (n=150)
    (n=102)
    (n=414)
    0.5 mg
    1.25 mg
    (n=422)
    (n=423)
    Mean lymphocyte count (x10^9 / L)
    Francis G et al. AAN April 2011; Lymphocytes and Fingolimod Temporal pattern and relationship with Infections (S30.001)
  • Incidence of overall infectionsper patient-year categorised by mean lymphocyte count, over 2 years (FREEDOMS)
    Infections by lymphocyte count(all treatment groups)
    Overall infections
    2.0
    1.6
    1.2
    Incidence rate per patient-year of any infection
    0.8
    0.4
    0.0
    <0.2(n = 23)
    0.2-0.3(n = 169)
    0.3-0.4(n = 194)
    0.4-0.5(n = 169)
    0.5 -0.7(n = 150)
    >0.7(n = 102)
    Placebo(n = 414)
    0.5 mg(n = 422)
    1.25 mg*(n = 423)
    Mean lymphocyte count (x109 / L)
    Fingolimod
    Data are for the FREEDOMS core study group
    Francis G et al. Presentation S30.001 at AAN 2011
  • Fingolimod preserved immune response to novel antigens in healthy volunteers
    Increase in anti-KLH IgG levels from pre-immunisation
    Increase in anti-PPV-23 IgG levels from pre-immunisation
    Placebo (n = 22)
    Fingolimod 0.5 mg (n = 22)
    Fingolimod 1.25 mg* (n = 22)
    Responder rate (%)
    Responder rate (%)
    Ability to increase T cell-dependent and T cell-independent antibody response in response to novel antigens was retained
    KLH, keyhole limpet haemocyanin; PPV, pneumococcal polysaccharides vaccine
    Schmouder R et al. Poster P412 presented at ECTRIMS 2010
  • Fingolimod preserved immune response to influenza vaccination in patients with MS
    After vaccination, in patients with MS treated with fingolimod
    vaccine-triggered T cells in blood were similar to healthy controls
    increases in anti-influenza A / B IgM and IgG similar to those in healthy controls
    Anti-influenza A IgG
    Anti-influenza B IgG
    Seroprotected patients (%)
    Seroprotected patients (%)
    Days
    Days
    Healthy controls (n = 18)
    MS fingolimod (n = 14*)
    *Six patients received fingolimod 0.5 mg and eight patients received fingolimod 1.25 mg; Mehling M et al. Ann Neurol 2011
  • Effect of fingolimod on heart rate: lowest heart rate >45 bpm in >97% of patients
    +Includes all available data from Phase II and Phase III core and extension studies with treatment durations varying between 1 to 6 years – data cut-off from 120 day safety update*Lowest HR of 36 bpm 3 hours post-dose, asymptomatic, treated with atropinePresentation FDA-Advisory Committee Meeting June 10, 2010
  • First dose effects of fingolimod on heart rate
  • Fingolimod : cardiac electrophysiological activity
    • Fingolimod, via S1PRs, activates a G-protein-activated inwardly rectifying K (GIRK) channel
    • The resulting current, IKACh, causes sinus slowing and increased AV nodal conduction and refractoriness1
    • Electrophysiological effects are transient due to receptor internalization/desensitization despite continued exposure with higher plasma drug concentrations
    1Koyrakh L et al. Am J Transplant 2005;5:529–36ACh, acetylcholine; AV, atrioventricular; K, potassium; M2, muscarinic acetylcholine receptor 2
  • Transienteffect of fingolimod on heart rate
    • Mild symptomatic bradycardiaobserved in 0.5% of patients receiving fingolimod 0.5 mg
    • The HR changes attenuated with continued therapy and returned to baseline levels by month 1
    Pooled FREEDOMS and TRANSFORMS safety population. Data are mean ± SD. AV, atrioventricular
    DiMarco JP et al. Poster P830 at ECTRIMS 2010
  • Transient dose-dependent slowing of AV conduction after first fingolimod dose
    AV conduction changes attenuated with continued therapy and no effect on conduction system observed by month 1 .
    FREEDOMS 2-year/TRANSFORMS 1-year safety population
  • An average increase of blood pressure of 2 mmHg systolic and 1 mmHg diastolic was seen with fingolimod after 2 months which stabilized by 6 months
    Systolic & Diastolic Blood Pressure over Time: Safety population (FREEDOMS :D2301)
    Presentation FDA-Advisory Committee Meeting June 10, 2010
  • Ophthalmic Effects of Fingolimod
  • Clinical Characteristics of 16 Macular oedema (ME) Patients in MS Clinical Studies
    Total no of patients studied n= 2615
    Zarbin M et al.AAN Aprill 2011; Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in Multiple Sclerosis (MS) (Poster 208)
  • Hepatic effects of Fingolimod
  • ALT / Bilirubin
    FREEDOMS 2 year safety population
    ALT: Alanine transaminase; ULN: Upper limit of normal
  • Adverse events: fingolimod compared with placebo
    Higher with placebo
    Higher with fingolimod 0.5 mg
    Overall AEs
    Hepatic enzyme increased
    Leukopenia
    Lymphopenia
    Gamma-glutamyltransferase increased
    Tinea versicolour
    Migraine
    Alanine aminotransferase increased
    Vision blurred
    Bronchitis
    Back pain
    Hypertension
    Diarrhoea
    Dyspnoea
    Urinary tract infection
    Micturition urgency
    Musculoskeletal stiffness
    Somnolence
    0.016
    0.002
    0.125
    1
    8
    64
    512
    Fingolimod 0.5 mg (N = 425)
    Placebo (N = 418)
    Relative risk with 95% CI
    Safety population
    Presentation FDA-Advisory Committee Meeting June 10, 2010; Collins AW et al. Poster P843 at ECTRIMS 2010
  • Adverse events: fingolimod compared with IFNβ-1a IM
    Higher with IFNβ-1a IM
    Higher with fingolimod 0.5 mg
    Overall AEs
    Gamma-glutamyltransferase increased
    Hepatic enzyme increased
    Alanine aminotransferase increased
    Hypertension
    Bronchitis
    Depression
    Arthralgia
    Myalgia
    Pyrexia
    Infusion-related reaction
    Influenza-like illness
    Chills
    0.004
    0.016
    0.063
    1
    4
    0.250
    16
    64
    256
    Fingolimod 0.5 mg (N = 429)
    IFNβ-1a IM (N = 431)
    Relative risk with 95% CI
    Safety population
    Presentation FDA-Advisory Committee Meeting June 10, 2010
  • Safety conclusions
    Based on > 4,500 patient-years in > 2,600 MS patients with comprehensive multi-organ safety assessments in all studies
    Overall incidence of SAEs and AEs leading to drug discontinuation similar between 0.5 mg dose and comparator (placebo & IFNβ-1a IM)
    Similar incidence for overall (with the exception of LRTIs) and serious/severe infections in fingolimod and comparator arms (IFNβ-1a IM, or placebo)
    No clear relationship between lymphocyte count, mean or nadir, and infection
    No signal for malignancy, but long-term risk including lymphomas must be closely followed as part of a Risk Management Plan
    Data in pregnancy is limited – strict contraception recommended in females of childbearing potential
    Fingolimod database has >90% power to detect serious events occurring more frequently than 1/3000 patient-years (1/1500 patients)
  • Safety conclusions
    Related to specific mode of action
    Transient Bradyarrhythmias on treatment initiation
    symptomatic in <0.5% for fingolimod 0.5mg
    ECG changes: mainly transient 1st and 2nd degree type 1 AV block (Wenckebach) on Day 1 of treatment;
    Macular oedema
    Fingolimod 0.5mg is associated with low incidence (0.2%)
    Most ME cases diagnosed within 3-4 months of treatment initiation and resolved after study drug discontinuation
    Elevation of liver enzymes
    Asymptomatic dose-dependent elevations of liver enzymes (8% had 3-fold increase in 0.5 mg group)
    No patient developed liver failure
  • Where Might Fingolimod Fit in the Treatment Algorithm?
    Natalizumab
    Immuno-suppressive
    Therapies
    Fingolimod
    Efficacy
    ?
    IFNβGA
    Burden of Therapy
    Factors affecting burden of therapy include convenience, tolerability, shortterm and longterm safety.
    GA=glatiramer acetate.
    75
  • Where Might Fingolimod Fit in the Treatment Algorithm?
    Natalizumab
    Immuno-suppressive
    Therapies
    Fingolimod
    Efficacy
    IFNβGA
    Burden of Therapy
    Factors affecting burden of therapy include convenience, tolerability, shortterm and longterm safety.
    GA=glatiramer acetate.
    76
  • Interdisciplinary Team of the MS-Center in Basel
  • Thank you for
    your attention !